Alerta

Reduction of viral disease transmission by avian antibodies

Resumen de: US20260354407A1

Formulations of egg powders with avian antibodies that act as mucosal protectants are provided. The formulations are effective for protecting the mucosal membranes in the pharyngeal area of an individual from viral infections. Formulations effective for reducing infections of SARS-CoV-2 in individuals are provided. Formulations are also effective for reducing transmission of viral disease. The formulations are tablets, candies, gummies, throat lozenges, and powders for administering to the pharyngeal area. Methods for administering the formulations for reducing viral disease such as Covid-19 are disclosed.

SARS-COV-2 BINDING AGENTS AND USES THEREOF

Resumen de: US20260356921A1

The invention relates to SARS-CoV-2 binding agents and uses thereof.

VACCINE USING M2/BM2-DEFICIENT INFLUENZA VECTORS

Resumen de: US20260355305A1

The invention provides a recombinant virus comprising an influenza viral backbone, wherein the influenza viral backbone comprises PB1, PB2, PA, NP, M, NS, HA, and NA gene segments, wherein at least one of the PB1, PB2, PA, NP, M, NS, HA, and NA gene segments comprises at least one nucleotide sequence that encodes one or more antigens. The invention provides a recombinant virus wherein the antigen is an immunogenic fragment of SARS-COV-2 spike glycoprotein. The invention also provides a pharmaceutical formulation and a method of eliciting an immune response.

SARS-CoV-2 Vaccines and Antibodies

Resumen de: US20260355302A1

The invention describes a method of generating antibodies to a mixture of SARS-COV-2 peptidogenic proteins or polynucleotides encoding SARS-COV-2 peptidogenic proteins wherein the SARS-COV-2 peptidogenic protein has altered conformational dynamics as compared to a SARS-COV-2 starting protein and wherein the SARS-COV-2 peptidogenic protein has a similar conformation to the SARS-COV-2 starting protein. The SARS-COV-2 peptidogenic proteins can be used to induce an immune response, which can lead to the generation of antibodies and/or can be used to vaccinate a mammal.

CORYNEBACTERIUM STRAINS, COMBINATIONS, AND LYOPHILIZED FORMULATIONS THEREOF FOR USE IN THE PREVENTION OF A VIRAL INFECTION

Resumen de: US20260355261A1

The invention relates to Corynebacterium strains capable of reducing the expression of cathepsin, and their combinations for use in the prevention of a viral infection, in particular SARS-CoV-2 infection, or for use in the prevention of an infection by an enveloped respiratory virus in a subject, wherein said virus uses cathepsin entry route for entry into the cell of the subject. In particular, said virus is SARS-CoV-2 omicron variant. The invention also relates to lyophilized formulations comprising Corynebacterium strains or combinations thereof, and a cryoprotectant, for use in the prevention of an infection by an enveloped respiratory virus, preferably a SARS-CoV-2 virus in a subject. Preferably, the formulation is administered to the upper respiratory tract of the subject.

IMPROVED COVID ANTIGEN CODING SEQUENCES

Resumen de: AU2025375915A1

Codon-optimized nucleic acids encoding the XBB 1.5 or KP.2 SARS-CoV-2 protein and their use are provided.

INHIBITORS AND USES THEREFOR

Resumen de: US20260355171A1

Disclosed are compounds of Formula I and their use as inhibitors of the viral protease non-structural protein 5 (NSP5). Typically, the NSP5 is derived from a coronavirus, more typically from SARS-CoV-2. More particularly, the invention relates to compounds of Formula (I) and their use for treating or inhibiting the development of a condition in which inhibiting NSP5 activity is associated with effective treatment or inhibition, including a coronavirus infection, for treating or inhibiting the development of a condition associated with a coronavirus infection, for treating or inhibiting the development of neurological symptoms of, and/or neurological complications associated with, a coronavirus infection and for treating or inhibiting the development or progression of long COVID following SARS-CoV-2 infection.

Self-replicating RNA and uses thereof

Resumen de: AU2026257536A1

The present disclosure relates to self-replicating RNA encoding an antigen from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and uses thereof. Specifically, the disclosure provides a self-replicating RNA or a monocistronic self- replicating RNA comprising a nucleotide sequence encoding an antigen operably linked to a subgenomic promoter, wherein the antigen is from SARS-CoV-2, and wherein the antigen is a spike (S) protein or a nucleocapsid (N) protein. ct c t

USE OF D-XYLOSE TO STIMULATE GLYCOSAMINOGLYCAN BIOSYNTHESIS

Resumen de: US20260355225A1

The invention relates to a formulation comprising at least one compound selected from D-xylose, esters thereof, oligosaccharides comprising D-xylose, and/or β-D-xylosides, for use in stimulating the biosynthesis of glycosaminoglycans, preferably at least one selected from heparan sulfate, dermatan sulfate and chondroitin sulfate, in a human patient, by administering between 1 and 10 doses per day of a composition having a mass of 500 mg to 10 g of said compound. Preferably, said formulation is for use in the prevention or treatment of infections with viruses using syndecans and/or glypicans as cell receptors, such as SARS-CoV-2 or HIV, or in the prevention or treatment of type 2 diabetes or of insulin resistance. The invention also relates to the use of an oral or nasal food supplement composition in healthy subjects to stimulate glycosaminoglycan biosynthesis.

System and Method for Binding to and Inhibiting the Activity of the SARS-CoV-2 Surface Spike Protein (6VSB) using Tulsi Extracts

Resumen de: US20260345710A1

0000 A system and methods for binding to and inhibiting the activity of the SARS-CoV-2 surface spike protein (6VSB) using tulsi extracts from ocimum x africanum is disclosed. One method includes extracting tulsi extracts and administering them to a person through various delivery mechanisms, such as tea, intravenous (IV) fluid, or encapsulated capsules. Another method includes encapsulating fenugreek seeds and neem with tulsi extracts in capsules to enhance the binding and inhibition of SARS-CoV-2 surface spike proteins. Additionally, the invention covers the use of intravenous (IV) fluid containing tulsi extracts, fenugreek seed extracts, and neem extracts for binding to and inhibiting the activity of SARS-CoV-2 surface spike proteins (6VSB).

System and Method for Inhibiting the Nain Protease (Mpro) of SARS-CoV-2

Resumen de: US20260345558A1

A novel benzimidazole-based compound designed to inhibit the main protease (Mpro) of SARS-CoV-2, the virus responsible for COVID-19 a method of manufacture, and method of use is disclosed. The compound features a benzimidazole core with a fluorine atom at the 7-position, facilitating pi-stacking interactions with His41 in the Mpro active site. The chiral side chain includes a modified amphetamine backbone with a chiral carbon bearing a methyl group and an isobutyl group, filling the hydrophobic S2 pocket of Mpro. The nitrile warhead forms a covalent bond with the catalytic Cys145 of Mpro, ensuring irreversible inhibition. Additionally, the glutamine-mimicking side chain forms hydrogen bonds with Gln189, Glu166, and Thr190 in the Mpro active site. The compound can be administered in a pharmaceutical composition to treat COVID-19.

METHODS OF TREATING FIBROSIS

Resumen de: AU2026257502A1

Abstract The present specification provides methods and compositions for treating fibrosis, particularly pulmonary fibrosis. The method for treating fibrosis comprising administering means for inhibiting Gli1 to a patient in need thereof. The pulmonary fibrosis may be idiopathic or arise following an infection of the lung. The lung infection can be by SARS-CoV-2. Lung function stabilizes or is improved as a result of treatment. Abstract

NUCLEIC ACID BASED VACCINE

Resumen de: US20260345768A1

0000 The present invention is directed to nucleic acids suitable for use in treatment or prophylaxis of an infection with a coronavirus, such as a Coronavirus SARS-CoV-2 variant, or a disorder related to such an infection, such as COVID-19. The present invention is also directed to compositions, and vaccines. The compositions and vaccines comprise at least one of said nucleic acid sequences, and nucleic acid sequences in association with a lipid nanoparticle (LNP). The invention is also directed to first and second medical uses of the nucleic acids, the composition, the vaccine, and the kit, and to methods of treating or preventing a coronavirus infection, such as a Coronavirus infection from a SARS-CoV-2 variant.

SYNTHETIC SURFACTANTS FOR INHIBITING CORONAVIRUS INFECTION

Resumen de: US20260345742A1

Compositions and methods are described that are useful for treating and preventing viral infections, such as those by SARS-CoV-2. It is discovered herein that synthetic surfactants such as SMB (SEQ ID NO:7) and B-YL (SEQ ID NO:27) can bind to SARS-CoV-2 Receptor Binding Domain (RBD) and the ACE2 receptor, thereby inhibiting the interaction between the virus and its target cells in the lung, minimizing the infectivity of the virus.

ANTIVIRAL NUCLEIC ACIDS AND COMPOSITIONS

Resumen de: US20260347852A1

0000 The present invention relates generally to compositions and methods for inhibiting the replication of coronaviruses and treating diseases caused by coronavirus infection. More specifically, the invention provides nucleic acids capable of inhibiting coronavirus (e.g. SARS-CoV-2) replication and their use in treating patients infected by the virus

USE OF GRFT AND FUSION PROTEIN GREK1 THEREOF IN INHIBITING PARAMYXOVIRUS OR NOVEL CORONAVIRUS INFECTIONS

Resumen de: WO2026227737A1

Disclosed in the present invention are a GRFT protein, a GREK1 fusion protein, a nucleic acid encoding same, and use thereof in the preparation of a medicament for preventing or treating: a) paramyxovirus or novel coronavirus infections, and/or b) diseases caused by paramyxovirus or novel coronavirus infections, wherein the GRFT protein comprises an amino acid sequence set forth in SEQ ID NO: 2, and the GREK1 fusion protein comprises an amino acid sequence set forth in SEQ ID NO: 1.

METHODS AND SYSTEMS FOR DETECTION OF PATHOGENS

Resumen de: US20260347955A1

0000 Disclosed are methods, compositions and systems for detecting the presence or absence of a pathogen in a sample. The method may include the steps of obtaining a sample from the subject and treating the sample with heat to inactivate any pathogen present in the sample. The method may further include the step of treating the sample to concentrate any pathogen present in the sample. Also, the method may include isolate a pathogen-specific nucleic acid from the heat-inactivated sample and detecting the presence or absence of the isolated pathogen-specific nucleic acid. In certain embodiments, the methods and/or systems may be used to detect SARS-CoV-2. The method may employ real time RT-PCR to provide results in about 3 hours or less.

PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING CORONA VIRUS INFECTION

Resumen de: CA3328600A1

The object of the present invention is to provide an effective antiviral agent against COVID-19. The object can be solved by (1) A polypeptide comprising an amino acid sequence selected from the group consisting of the amino acid sequence of SEQ ID NO: 1, the amino acid sequence of SEQ ID NO: 2, the amino acid sequence of SEQ ID NO: 3, the amino acid sequence of SEQ ID NO: 4, the amino acid sequence of SEQ ID NO: 5, the amino acid sequence of SEQ ID NO: 6, the amino acid sequence of SEQ ID NO: 7, and the amino acid sequence of SEQ ID NO: 8, or (2) a polypeptide comprising an amino acid sequence, in which 1 amino acid is substituted in the amino acid sequence of SEQ ID NO: 1, the amino acid sequence of SEQ ID NO: 2, the amino acid sequence of SEQ ID NO: 3, the amino acid sequence of SEQ ID NO: 4, the amino acid sequence of SEQ ID NO: 5, the amino acid sequence of SEQ ID NO: 6, the amino acid sequence of SEQ ID NO: 7, and the amino acid sequence of SEQ ID NO: 8, and having an anti-virus activity against coronavirus, wherein the polypeptide has an O-glycosidic linked sugar chain.

ULTRAPOTENT BROARDLY NEUTRALIZING ANTIBODIES AGAINST SARS-COV-2 VARIANTS AND METHODS OF USE THEREOF

Resumen de: WO2025140539A1

Provided is in the field of immunology. Provided are broadly neutralizing antibodies against SARS-COV-2 variants, compositions and methods of prevention and treatment of SARS-COV-2 infection or transmission.

DAPSONE FORMULATIONS AND METHODS OF USING SAME

Resumen de: EP4834433A2

0001 A method for treating patients with COVID-19 and/or other respiratory conditions include administering a dosage of 75-100 milligrams of dapsone twice daily. A variety of dapsone formulation and delivery devices are disclosed, including an inhaler, nasal spray, nasal gel, otic formulation, intravenous formulation, oral solution, oral suspension, patch and suppository.

Method for diagnosing pulmonary tuberculosis in combination with certain viral infections in patients with secondary immunodeficiency

Resumen de: MD1994Y

The invention relates to medicine, in particular to phthisiology and pulmonology, clinical immunology, allergology and pathophysiology, and can be used for diagnosing pulmonary tuberculosis in combination with certain viral infections in patients with secondary immunodeficiency.Summary of the invention consists in that an immunological study of peripheral blood is performed with the determination of the following indicators: the number of lymphocytes, the functional activity of lymphocytes in the test using the transformation reaction of lymphocyte blasts with phytohemagglutinin, the glucose consumption from the supernatant obtained from the cultivation of lymphocytes in the test using the transformation reaction of lymphocyte blasts with phytohemagglutinin, the activity of lactate dehydrogenase and lymphocyte aldolase, and if the results of the determined indicators show a deficit within <1/3 compared to the indicators in practically healthy sunjects, monoinfection with tuberculosis is diagnosed; if the results of the indicators show a deficit of 1/3…2/3 compared to the indicators in practically healthy subjects, the combination of tuberculosis with infection with the human immunodeficiency virus is diagnosed; and if the results of the indicators show a deficit of >2/3 compared to the indicators in practically healthy subjects, the combination of tuberculosis with human immunodeficiency virus infection and COVID-19 is diagnosed.

METHODS FOR PREDICTING POST-ACUTE SEQUELAE OF VIRAL INFECTIONS USING INTERFERON STIMULATED GENE PROTEINS

Resumen de: WO2026226538A1

Described herein are systems, methods, and kits for predicting post-acute sequelae of a viral infection in a subject. The disclosed methods may comprise obtaining a biological sample from the subject during an acute phase of the viral infection, measuring a level of at least one interferon stimulated gene protein in the biological sample, and determining a risk of the subject developing post-acute sequelae based on the measured level of the at least one interferon stimulated gene protein. In some embodiments, the viral infection is a SARS-CoV-2 infection. Also described herein are methods for treating or preventing post-acute sequelae of a viral infection in a subject in need thereof.

LIVE ATTENUATED SARS-COV-2 AND A VACCINE MADE THEREOF

Resumen de: US20260335429A1

It is provided a polynucleotide encoding a) severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein; and/or b) at least one non-structural SARS-CoV-2 protein selected from the group consisting of non-structural protein 7, non-structural protein 8, non-structural protein 9, non-structural protein 10, non-structural protein 11, non-structural protein 12, an endoribonuclease, and a 2′-O-methyltransferase, wherein the polynucleotide comprises or consists of at least one sequence part comprising codon-pair deoptimizations in comparison to the SARS-CoV-2 genome, and wherein the polynucleotide further comprises a furin cleavage site modification resulting in a loss of a furin cleavage site being naturally present in the SARS-CoV-2 genome.

COMPOSITIONS AND METHODS OF MINIMIZING LONG COVID

Resumen de: US20260335274A1

Pharmaceutical formulations for nasal administration are disclosed. The pharmaceutical formulation contains a green tea catechin derivative (such as an epigallocatechin-3-gallate-palmitate); and preferably further includes a carbohydrate (such as a polysaccharide); and a pharmaceutically acceptable carrier. The pharmaceutical formulation has a viscosity sufficient to maintain the green tea catechin derivative in contact with nasal epithelial cells optionally for at least about 30 minutes in the presence of mucus. Also described are methods of using the nasal formulations for preventing, reducing, and/or treating neurological damages caused by exposure to a virus, such as a SARS-CoV-2. For example, the disclosed pharmaceutical formulations can treat or prevent one or more symptoms of long COVID in an infected subject, and/or repair the damaged nasal epithelial cells, neuroepithelial cells, vascular cells, and/or neurons and restore their functions in a subject recovered from a COVID infection, such as the olfactory function of these cells.

RECOMBINANT mRNA VACCINE AGAINST SARS-COV-2

Nº publicación: WO2026224730A1 29/10/2026

Solicitante:

COUNCIL OF SCIENT & INDUSTRIAL RESEARCH [IN]
COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH

Resumen de: WO2026224730A1

Most of the vaccines developed against SARS-CoV-2 are based on structural proteins of the virus, especially the spike protein. Antibody dependent enhancement of infection is a common hurdle that comes in the way of vaccine development when structural proteins are used. As mutations accumulate a vaccine that might not be showing antibody dependent enhancement might start showing enhancement of infection based on the mutations that emerge. Also, spike protein is heavily prone to mutations thus requiring next generation vaccines based on mutations that might lead to escape from neutralizing antibodies. In our invention we have targeted a non-structural protein (NSP3) for designing a mRNA based vaccine candidate. As this is based on a non-structural protein we do not anticipate antibody dependent enhancement of infection. We used the MacI domain of this protein. We have added a secretory signal to enable secretion of MacI so that all possible immunological pathways are stimulated. Mice based immunizations showed effective IgG production against MacI that also lasted for extended period time post prime boost immunization.